Hospira continues pursuit of Javelin

LAKE FOREST, Ill. Generic injectable drug maker Hospira said Thursday that it had extended its $145 million offer to acquire Javelin Pharmaceuticals.

The offer had been set to expire at the end of Wednesday, but has been extended to the end of June 16.

Hospira originally offered to acquire Javelin in April.